Clinical Trial Update: Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination or sequencing of vemurafenib, cobimetinib, and atezolizumab in patients with high-risk, resectable melano…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cotellic (cobimetinib)
• Tecentriq (atezolizumab)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Fondazione Melanoma Onlus | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING